Home > Healthcare > Medical Devices > Therapeutic Devices > Intensity Modulated Radiation Therapy Market

Intensity Modulated Radiation Therapy Market Share

Report ID: GMI7540
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Intensity Modulated Radiation Therapy Market Share

The intensity modulated radiation therapy industry is fragmented, with key players including Siemens Healthineers, IBA, Hitachi, Ltd., and others dominating the market space. These companies focus on product innovation, geographical expansion, and partnerships to secure substantial market share. For instance, in December 2022, IBA won a contract for the installation of ten proton therapy systems in Spain, which is being funded by the Amancio Ortega Foundation. The project valued over USD 229 million has been signed with the Spanish Ministry of Health under a public-private partnership agreement. Such contracts strengthen company’s position in the regional market.

Some of the eminent market participants operating in the intensity modulated radiation therapy industry include:

Siemens Healthineers
ViewRay, Inc.
IBA Dosimetry
Mevion Medical Systems
Hitachi, Ltd.
RaySearch Laboratories AB
Brainlab AG
ProTom International
Mitsubishi Electric Corporation
Sumitomo Heavy Industries, Ltd.
ProNova Solutions, LLC
Varian Medical Systems, Inc.
Elekta AB
Accuray Incorporated
Panacea Medical Technologies Pvt. Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intensity modulated radiation therapy industry size was USD 2.2 billion in 2022 and is estimated to reach USD 3.6 billion by 2032 due to the increasing prevalence of cancer worldwide

Proton radiation type segment garnered USD 420 million in 2022 owing to the ongoing advancements in pencil beam scanning.

The breast cancer application segment accounted for over 26% of the intensity modulated radiation therapy market share in 2022 due to the increasing prevalence of breast cancer.

U.S. intensity modulated radiation therapy industry exceeded USD 766 million in revenue in 2022 led by the rising incidence of cancer in the region.